

# 1 **Longitudinal dynamics of *Streptococcus pneumoniae* carriage and SARS-CoV-2 infection in** 2 **households with children.**

3  
4 Willem R. Miellet<sup>1,2#</sup>, Rob Mariman<sup>2</sup>, Dirk Eggink<sup>2</sup>, Mioara A. Nicolaie<sup>3</sup>, Janieke van Veldhuizen<sup>2</sup>, Gerlinde  
5 Pluister<sup>2</sup>, Lisa M. Kolodziej<sup>5</sup>, Steven F.L. van Lelyveld<sup>4</sup>, Sjoerd M. Euser<sup>6</sup>, Elisabeth A.M. Sanders<sup>1,2</sup>,  
6 Marianne A. van Houten<sup>7</sup>, Krzysztof Trzciński<sup>1</sup>

7  
8 <sup>1</sup>Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University  
9 Medical Center Utrecht (UMCU), The Netherlands;

10 <sup>2</sup>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM),  
11 Bilthoven, The Netherlands;

12 <sup>3</sup>Department of Statistics, Data Science and Modelling, National Institute for Public Health and the  
13 Environment (RIVM), Bilthoven, The Netherlands;

14 <sup>4</sup>Department of internal medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands;

15 <sup>5</sup>Present affiliation: Department of Medical Microbiology and Infection Prevention, Amsterdam University  
16 Medical Centres, University of Amsterdam, Amsterdam, The Netherlands;

17 <sup>6</sup>Regional Public Health Laboratory Kennemerland, Haarlem, The Netherlands;

18 <sup>7</sup>Department of pediatrics, Spaarne Gasthuis, Haarlem, The Netherlands.

19  
20 #corresponding author:

21 UMCU, Heidelberglaan 100, HP – G04.614, 3508 AB Utrecht, The Netherlands

22 w.r.miellet-2@umcutrecht.nl

23 Phone: +31 638259782

24  
25 Running title: Pneumococcus & SARS-CoV-2 dynamics

## 26 **ABSTRACT**

### 27 **Background:**

28 To characterize interferences between *Streptococcus pneumoniae* and SARS-CoV-2 we investigated the  
29 longitudinal patterns of viral infection and pneumococcal carriage in households infected with SARS-CoV-2.  
30

### 31 **Methods:**

32 SARS-CoV-2 and pneumococcus were detected with quantitative molecular methods in saliva from members  
33 of eighty participating households. Samples were collected between October 2020 and January 2021 from  
34 n=197 adults and n=118 children of which n=176 adults and n=98 children had a complete set of ten samples  
35 collected within 42 days since enrolment. Time-dependent Cox models were used to evaluate the associations  
36 between SARS-CoV-2 and pneumococcal carriage.

### 37 **Results:**

38 In the entire cohort, cumulative pneumococcal carriage and SARS-CoV-2 infection rates were 58% and 65%,  
39 respectively. Pneumococcal abundances were associated with an increased risk of SARS-CoV-2 infection (HR  
40 1.14, 95% CI, 1.01 – 1.29,  $P=0.04$ ) and delayed clearance of SARS-CoV-2 infection (HR 0.90, 95% CI, 0.82  
41 – 0.99,  $P=0.03$ ). Elevated viral loads were observed among pneumococcal carriers and individuals with high  
42 overall bacterial 16S abundances, however, there were no longitudinal differences in viral loads in linear  
43 mixed-effects models. Individuals with high 16S abundances displayed delayed viral clearance (HR 0.65, 95%  
44 CI 0.55 – 0.78,  $P<0.0001$ ).

### 45 **Conclusions:**

46 Although we found insufficient evidence for a strong impact of SARS-CoV-2 infection on pneumococcal  
47 carriage. Results from the current study suggest that pneumococcal carriers may have an increased risk of  
48 SARS-CoV-2 infection and high pneumococcal abundances and 16S abundances may be associated with  
49 elevated viral loads and delayed clearance of SARS-CoV-2 infection.  
50

51 **Keywords:** *Streptococcus pneumoniae*, pneumococcal carriage, SARS-CoV-2, COVID-19, co-infection

## 52 INTRODUCTION

53 Epidemiological studies and animal co-infection models suggest strong synergistic interactions between  
54 certain respiratory viruses and *Streptococcus pneumoniae* [1]. For one, influenza virus, respiratory syncytial  
55 virus, and rhinovirus provoke host immune responses that can disturb colonizing resistance induced by the  
56 microbiota of the upper respiratory tract (URT), mute innate immune recognition of pneumococcus and  
57 increase the risk of secondary pneumococcal pneumonia [2-8]. Concomitantly, inflammation associated with  
58 pneumococcal colonization may facilitate viral respiratory infections [9-12].

59 Relatively little is known about interferences between pneumococcus and SARS-CoV-2. However, between  
60 2020 and 2021 multiple countries reported declines in incidence of invasive pneumococcal disease (IPD) [13-  
61 15] and co-infections with pneumococcus were rare in COVID-19 patients [14, 16]. Although high rates of  
62 empiric antibiotic therapy in severe COVID-19 cases could have diminished pneumococcal disease incidence  
63 and contribute to low co-infection rates [17-19], the decline in IPD was primarily attributed to non-  
64 pharmaceutical interventions (NPIs) [13, 14]. It has been assumed that NPIs that included social distancing,  
65 wearing facemasks, closure of schools, restaurants, shops and cultural facilities and the advice to work from  
66 home limited pneumococcal transmission, thereby reducing the prevalence of pneumococcal carriage and  
67 consequently the incidence of IPD during pandemic [13]. However, several studies have reported that  
68 pneumococcal carriage rates in children were relatively unaffected during the pandemic when compared with  
69 the pre-COVID-19 period [15, 20]. Danino *et al.* concluded that declines in pneumococcal disease were likely  
70 driven by declines in seasonal respiratory virus circulation and not by reduced pneumococcal transmission  
71 [15].

72  
73 URT inflammation associated with pneumococcal colonization may facilitate propagation of viral infection  
74 in the airways of exposed individuals [9-11]. While few clinical studies have investigated co-infections  
75 between SARS-CoV-2 and pneumococcus, none of the published papers have reported on possible  
76 interference between the two pathogens within households and studied longitudinal effects. To investigate the  
77 effect of pneumococcal colonization on SARS-CoV-2 infection and *vice versa*, we have conducted a  
78 longitudinal household study using molecular diagnostic methods to detect SARS-CoV-2 and pneumococcus  
79 in self-collected saliva samples [6, 21]. In our study, we found insufficient evidence for a strong impact of  
80 SARS-CoV-2 infection on pneumococcal carriage. However, pneumococcal carriers, children in particular,  
81 exhibited an increased risk of SARS-CoV-2 infection. High pneumococcal abundances and 16S abundances  
82 were associated with elevated viral loads and delayed clearance of SARS-CoV-2 infection.

## 83 MATERIALS and METHODS

### 84 Study Design and Ethics statement

85 We investigated pneumococcal carriage in a prospective observational cohort study [21] conducted between  
86 October 2020 and January 2021. Households were included in the study when a household member below 65  
87 years of age tested positive for SARS-CoV-2 using qPCR within 72 hours prior to inclusion and at least 2  
88 other household members consented to participate in the study. Enrolled study participants were asked to self-  
89 collect saliva samples over a period of six weeks. Written informed consent was obtained from all study  
90 participants or from their legal guardians. The study was reviewed and approved by the Medical Ethical  
91 Committee of the Vrije Universiteit university Medical Centre (Vumc), The Netherlands (reference nr.  
92 020.436).

### 94 Sample Collection

95 As previously described by Kolodziej *et al.*, saliva samples were collected on day 1, 3, 5, 7, 10, 14, 21, 28, 35,  
96 and 42 since inclusion [21]. In short, individuals aged  $\geq 5$  years were asked to collect saliva, by spitting  
97 approximately 2 ml into a Genefix Saliva Collection device without buffer (Isohelix). From individuals aged  
98  $< 5$  years saliva was collected with two Oracol (S10) sponges (Malvern Medical Developments). Samples were  
99 stored by participants in their home freezer and within three weeks transported on dry ice to the diagnostic  
100 laboratory for storage at  $-80^{\circ}\text{C}$ .

### 102 SARS-CoV-2 and *S. pneumoniae* detection with quantitative molecular methods

103 Nucleic acids were extracted from 200  $\mu\text{l}$  of saliva using a MagNApure 96 system (Roche) with Equine  
104 arteritis virus and yeast tRNA added as internal control and stabilizer, respectively. Nucleic acids were eluted  
105 into 50  $\mu\text{l}$  Tris EDTA buffer. To detect SARS-CoV-2, 5  $\mu\text{l}$  of the eluate was tested in reverse-transcriptase  
106 qPCR with primers and probe targeting the SARS-like beta coronavirus-specific *Egene* [22]. Pneumococcal  
107 DNA was detected by testing 5.5  $\mu\text{l}$  of a sample in single-plex qPCRs with primers and probes targeting DNA  
108 sequences within genes encoding for pneumococcal iron uptake ABC transporter lipoprotein (PiaB) [23], and  
109 major pneumococcal autolysin (LytA) [24] as previously described [25]. We quantified 16S with qPCR as a  
110 marker of overall bacterial abundance [6]. Molecular detection of pneumococcal serotypes is described in the  
111 Supplement.

### 113 Statistical Analysis

114 Data analysis was performed in R version 4.2.2. Samples were considered positive by qPCR for *piaB*, *lytA*  
115 and *Egene* when  $C_q$ s were below 40. For qPCR-based serotyping results concordance with *piaB/lytA* was  
116 required [26]. Intraclass correlations (ICCs (3,1)) were calculated in a two-way mixed-effects model with  
117 consistency relationship ( $piaB C_q = lytA C_q + \text{systematic error}$ ) and of single measurement type [27], and  
118 Bland-Altman plots [28] were used to assess agreement between qPCR measurements using the “irr” and  
119 “blandr” R packages, respectively. Unpaired and paired carriage rates were compared with Fisher’s exact test

120 and McNemar's test, respectively. Relative pneumococcal abundances were calculated by dividing  
121 pneumococcal abundances by overall bacterial abundances (16S). Bacterial and pneumococcal abundances  
122 were compared by means of a permutation test equivalent of Mann-Whitney U test with blocking by age group  
123 [29]. Linear mixed-effects modeling was conducted to assess the association between SARS-CoV-2 infection  
124 and pneumococcal carriage status, and between SARS-CoV-2 infection and 16S abundances, where  
125 individuals at time 1 were classified as having low ( $<$  median at time 1) or high ( $\geq$  median at time 1) 16S  
126 abundance. A random intercept was used in linear-mixed effects model to account for longitudinal intra-  
127 individual variance, and to address inter-individual variance. The time to SARS-CoV-2 infection and time to  
128 SARS-CoV-2 infection clearance in relationship to pneumococcal carriage, pneumococcal abundance and log-  
129 transformed overall bacterial (16S) abundance were assessed by means of stratified time-dependent Cox  
130 proportional hazards models, where strata were defined by age groups. In order to estimate age-specific hazard  
131 rates (HR), two age groups were considered, children ( $<18$  years) and adults ( $\geq 18$  years). The proportionality  
132 assumption was tested using the Schoenfeld residuals test. Model selection was performed by means of the  
133 Akaike information criterion and model checking was done by comparing the model-based survival curves  
134 with the Kaplan-Meier estimator. A  $p$  value of  $<0.05$  was considered significant.

## RESULTS

Of 337 individuals from whom saliva was collected, 11 had incomplete questionnaire data and 52 fewer than ten samples collected. As such, analysis was limited to 274 (81.3.%) individuals of 80 households (**Table 1**). Sixty-five percent of individuals (177/274) and 95% (76/80) of households tested positive for SARS-CoV-2 infection in saliva during the six weeks of screening [21]. Per study design, almost all SARS-CoV-2 infections occurred within the first 10 days since enrolment and the number of SARS-CoV-2 infected individuals began to decline after the first 14 days of the study period [21].

### **Pneumococcal Carriage Prevalence Rates in Households with Individuals Infected with SARS-CoV-2**

Altogether, 160 individuals (58% of 274) tested positive for pneumococcus by qPCR. This corresponded to 40% (1083/2740) of samples positive for pneumococcus using a dual-target approach with *piaB* and *lytA* genes, with significant correlations between *piaB* and *lytA* C<sub>qs</sub> (**Fig. 1**) and ICCs of 0.89 (95% CI 0.87 – 0.90) indicative of good reliability. Similar ICCs were observed at each of the ten sampling events separately (**Fig. S1**). During a follow-up of six weeks cumulative pneumococcal carriage and SARS-CoV-2 infection rates were 58.4% (160 of 274) and 64.6% (177 of 274), respectively. We observed a mean pneumococcal carriage rate of 35.8% (98/274, 95% CI 30-42%) (**Table S1**). The proportion of pneumococcal carriers with SARS-CoV-2 infection was high during the first two weeks of the study with on average 54.1% of pneumococcal carriers concurrently positive for SARS-CoV-2 and a cumulative co-infection rate of 33.9% (93 of 274). Despite high co-infection rates, pneumococcal carriage rates remained relatively constant throughout the study period (**Fig. 2**), suggesting little impact of SARS-CoV-2 infection on pneumococcal carriage rates. Rates of pneumococcal carriage were highest among children <12 years of age (88.2%, **Table 1**) and households with young children (<5 years; n=15) displayed significantly increased rates of pneumococcal carriage compared with other households (Fisher's exact test,  $P < 0.0001$ , OR 7.7 [95% CI 3.1-22.8]).

### **Hazards Model Analysis**

We sought to evaluate the relationship between pneumococcal carriage and SARS-CoV-2 infection. To this goal, only samples from individuals who tested negative at enrolment were considered (n=121 individuals experiencing n=23 virus acquisition events). We fit a Cox proportional hazards model to the time to SARS-CoV-2 infection. In a multivariate model, pneumococcal abundances and 16S abundances were used as covariates. To account for events within the same family, we calculated robust standard errors for effects sizes. Next, we performed model selection (**Table S2, Fig. S2**). Using the multivariable model, pneumococcal abundances were associated with an increased risk for SARS-CoV-2 infection (HR 1.14, 95% CI, 1.01 – 1.29), whereas we did not find sufficient evidence for an association between 16S abundances and SARS-CoV-2 infection (HR 0.86, 95% CI, 0.58 – 1.27). The cumulative hazard rates across the study period were higher for children (HR 2.14) than for adults (HR 0.83), suggesting that the relationship between pneumococcal abundances and SARS-CoV-2 infection was primarily associated with children.



172 Next, we assessed the association between pneumococcal carriage and SARS-CoV-2 infection clearance. We  
173 therefore limited the analysis to samples from individuals who tested positive for SARS-CoV-2 at enrolment  
174 (n=153 individuals experiencing n=134 events) and we used stratified Cox regression analysis to model the  
175 time to SARS-CoV-2 infection clearance. Multivariate models that included covariates for pneumococcal  
176 abundance and 16S abundance, were considered for model selection (**Table S3, Fig. S3**). In the multivariable  
177 model both pneumococcal abundances (HR 0.90 95% CI, 0.82 – 0.99) and 16S abundances (HR 0.68 95% CI,  
178 0.55 – 0.78) before day 21 were significantly associated with a decreased risk for SARS-CoV-2 infection  
179 clearance (**Table S3**).

### 181 **Pneumococcal abundances among SARS-CoV-2 infected individuals**

182 We then sought to determine whether SARS-CoV-2 infection impacted pneumococcal abundances and  
183 bacterial presence in the upper respiratory airways. SARS-CoV-2 infected individuals exhibited significantly  
184 elevated pneumococcal abundances at day 10, 21 and 28 when compared with uninfected individuals (**Fig.**  
185 **S4A**). Likewise, significantly elevated 16S abundances among SARS-CoV-2 infected individuals were  
186 observed at day 10, 14, 21 and 28 (**Fig. S4B**). However, no significant differences between SARS-CoV-2  
187 infected and uninfected individuals were observed for pneumococcal relative abundances (**Fig. S4C**). In line  
188 with this, we did not observe considerable shifts in serotype carriage composition across the study period (**Fig.**  
189 **S5**).

### 191 **Increased viral loads in individuals carrying pneumococcus**

192 Thereafter, we quantified *Egene* as a marker of SARS-CoV-2 viral loads from individuals who tested positive  
193 for SARS-CoV-2 at enrolment and compared viral loads among pneumococcal carriers and noncarriers, and  
194 individuals with high or low 16S abundances. Significantly elevated viral loads were observed at multiple  
195 sampling time points for pneumococcal carriers when compared with noncarriers (**Fig. 3A**). Individuals with  
196 high 16S abundances also displayed significantly increased viral loads at multiple sampling events when  
197 compared with individuals with low 16S abundances (**Fig. 3B**). We subsequently modelled longitudinal  
198 trajectories of log-transformed viral loads using linear mixed-effects modelling. Trajectories were estimated  
199 from positive samples by censoring measurements with *Egene* C<sub>qs</sub> 40 or higher. We did not observe significant  
200 differences in longitudinal viral load trajectories between pneumococcal carriers versus noncarriers (**Fig. S6A-**  
201 **B**), and between individuals with high versus low 16S abundances (**Fig. S6C-D**).

## DISCUSSION

Interplay between respiratory viruses and pneumococcus are often synergistic drivers of respiratory infections [8, 30]. In the current study, we investigated whether associations exist between SARS-CoV-2 infection and pneumococcal carriage among children and non-elderly adults.

We observed high rates of pneumococcal carriage within households during nationwide implementation of NPIs in the Netherlands in 2020/2021 [31]. Despite high coinfection rates we have found insufficient evidence for a strong impact of SARS-CoV-2 infection on pneumococcal carriage rates and pneumococcal abundances. However, pneumococcal carriers exhibited an increased risk of SARS-CoV-2 infection and delayed viral clearance. Delayed viral clearance was also observed among individuals with high 16S abundances yet we observed no association between 16S abundances and SARS-CoV-2 infection rates. Both pneumococcal carriers and individuals with high 16S abundances exhibited increased SARS-CoV-2 viral loads at multiple sampling events. However, differences in longitudinal viral load trajectories among pneumococcal carriers or individuals with high 16S abundances were not significant.

Despite the imposition of NPIs and a decline in seasonal respiratory virus circulation during the study period [32] there was a substantial presence of pneumococcal carriage. Our observations are in line with reports by others [15, 20], suggesting that pneumococcal carriage prevalence rates did not decline during the COVID-19 pandemic and during NPIs. In contrast, the incidence of IPD dropped sharply during the 2020/2021 influenza season [13-15]. Danino *et al.* have attributed this decline in IPD to a drop in seasonal respiratory virus circulation following the imposition of NPIs and travel restrictions across countries [15].

Pneumococcal carriage rates were relatively constant throughout the study period. SARS-CoV-2 infected individuals exhibited elevated pneumococcal abundances and 16S abundances at several time points. However, no significant differences between SARS-CoV-2 infected and uninfected individuals were observed for relative pneumococcal abundances. Moreover, we have observed no substantial shift in sample serotype composition during the study period. Collectively, these observations suggest no marked impact of SARS-CoV-2 infection unique to pneumococcal colonization. Our findings are in line with studies describing that co-infections of SARS-CoV-2 and pneumococcus are uncommon [17, 33].

We performed Cox regression analysis to study possible interactions between SARS-CoV-2 and pneumococcus. As such, we modelled the impact of pneumococcal abundances independently from 16S abundances on SARS-CoV-2 infection rates and on SARS-CoV-2 infection clearance rates. Pneumococcal abundances were associated with an increased risk for SARS-CoV-2 infection, while there was insufficient evidence for an altered risk among individuals with high 16S abundances. High cumulative hazard rates among children but not among adults indicated that the relationship between pneumococcal abundances and SARS-CoV-2 infection was primarily associated with children.



239 In an observational study among older adults vaccination with PCV13 was reported to reduce the risk of  
240 COVID-19 diagnosis, COVID-19 hospitalization and fatal COVID-19 outcome [17], suggesting that PCV13  
241 vaccine-type pneumococcal carriage could predispose older adults to adverse outcomes associated with  
242 COVID-19. Another study among adults reported an increased odds of SARS-CoV-2 infection among  
243 pneumococcus-positive adults attending a COVID-19 testing clinic, yet in the same study pneumococcus-  
244 positive adults attending an outreach facility did not exhibit an increased odds of SARS-CoV-2 infection [34],  
245 suggesting that the association between pneumococcal carriage and SARS-CoV-2 may be non-causal. While  
246 previous studies focused on older individuals [17, 34], we investigated possible viral-bacterial interactions in  
247 children and non-elderly adults. Although we find that pneumococcal abundances were associated with  
248 increased SARS-CoV-2 infection rates, due to the limited number of events we cannot exclude that the reported  
249 association may have been attributable to confounding factors.

251 Findings from a study in the United Kingdom have suggested that IgA and CD4<sup>+</sup> T-cell responses to SARS-  
252 CoV-2 may be impaired among pneumococcal carriers [35]. Of note, CD4<sup>+</sup> T-cell mediated responses are also  
253 critical for clearance of pneumococcal colonization. Impairment of immune responses to SARS-CoV-2 also  
254 prolongs viral infection [36]. Consequently, one would expect delayed clearance of SARS-CoV-2 infection  
255 among pneumococcal carriers. Cox regression analysis of SARS-CoV-2 infection clearance rates indicated  
256 that high pneumococcal abundances were indeed associated with delayed clearance of SARS-CoV-2 infection.  
257 However, since high 16S abundances were also associated with delayed viral clearance, we do not find an  
258 association unique to pneumococcus.

260 High 16S abundances of the URT have previously been linked to dysbiosis of the URT microbiota in adults  
261 with community-acquired pneumonia [37]. The observed association between increased 16S abundances and  
262 delayed SARS-CoV-2 infection clearance in this study may therefore result from COVID-19 induced URT  
263 microbiome dysbiosis. Our observation is also in line with a study describing distinct URT microbiome  
264 composition profiles among hospitalized COVID-19 patients when compared with healthy individuals, which  
265 were linked to URT microbiota dysbiosis and were shown to correlate with COVID-19 severity [38].

267 Among study participants infected with SARS-CoV-2 at enrolment, pneumococcal carriers and individuals  
268 with high 16S abundances exhibited elevated SARS-CoV-2 viral loads at multiple sampling events, suggesting  
269 that presence of pneumococcal carriage could have impacted SARS-CoV-2 infection progression. Modelling of  
270 longitudinal viral load patterns indicated that pneumococcal carriage was not associated with altered viral load  
271 dynamics. Since elevated SARS-CoV-2 viral loads were observed among pneumococcal carriers and  
272 individuals with high 16S abundances, it appears likely that these findings are also related to COVID-19  
273 induced URT microbiota dysbiosis rather than exacerbation of SARS-CoV-2 infection due to pneumococcal  
274 colonization. Of note, since this study was conducted at a time prior to the emergence of SARS-CoV-2 variants

275 of concern (VOCs) in the Netherlands, interferences we observed could be affected by higher transmissibility  
276 of VOCs [31].

277  
278 As this study was primarily designed to evaluate the use of saliva in monitoring SARS-CoV-2 and to study  
279 SARS-CoV-2 household transmission dynamics [21], it has number of limitations for analysis of  
280 pneumococcal carriage and interactions between pneumococcus and SARS-CoV-2. The age group at greatest  
281 risk for both pneumococcal disease and COVID-19 was not included in this study, as such interactions  
282 between pneumococcus and SARS-CoV-2 specific for older age have been missed. The number of secondary  
283 cases of SARS-CoV-2 infections after the first sampling event were low, limiting the statistical power  
284 available for Cox regression analysis of SARS-CoV-2 infection. Moreover, the overall study size limited our  
285 ability to adjust for potential confounding factors in Cox regression analysis. Pneumococcal carriage episodes  
286 may have been missed due to the omission of a culture-enrichment procedure for pneumococcal detection  
287 [39].

288  
289 In conclusion, in a cohort of children and non-elderly adults we observed high rates of pneumococcal carriage  
290 and coinfections with SARS-CoV-2. While we find insufficient evidence for a strong impact of SARS-CoV-  
291 2 infection on pneumococcal carriage rates and pneumococcal abundances, we do observe an increased risk  
292 of SARS-CoV-2 infection among pneumococcal carriers, children in particular. Moreover, individuals with  
293 high pneumococcal abundances or 16S abundances exhibited delayed SARS-CoV-2 infection clearance and  
294 elevated viral loads, suggesting dysbiosis of the URT microbiome following SARS-CoV-2 infection.

295 **AUTHOR CONTRIBUTIONS**

296 W.R.M., E.A.M.S., M.A.v.H. and K. T. contributed to the conception and design of the study. D.E., J.v.V.,  
297 G.P., L.M.K., S.v.L., S.M.E. and R.M. participated in acquisition of data. R.M., D.E., S.v.L. and S.M.E.  
298 coordinated the laboratory analyses. W.R.M., R.M., M.A.N., J.v.V., L.M.K. and K.T. were responsible for  
299 data analyses and interpretation. W.R.M., M.A.N., L.M.K. and J.v.V. verified the underlying data W.R.M.,  
300 R.M. and K.T. wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

301  
302 **ACKNOWLEDGEMENTS**

303 We thank all the participants for their contribution to the study. We thank the team of the Public Health  
304 Services Kennemerland, for providing information to the (potential) participants; the Regional Public Health  
305 Laboratory (Streeklab) Kennemerland for laboratory analyses; and the research team of the Spaarne Gasthuis  
306 Academy, particularly Greetje van Asselt, Jacqueline Zonneveld, Sandra Kaamer van Hoegee, and Mara van  
307 Roermund for their hard work and Coen Lap for his efforts concerning the continuation of the SARSLIVA  
308 study. We thank the laboratory team from the virology department at National Institute for Public Health and  
309 the Environment (RIVM). We thank Tessa Nieuwenhuijsen for her assistance in the laboratory.

## REFERENCES

1. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis* **2008**; 198(7): 962-70.
2. Grijalva CG, Griffin MR, Edwards KM, et al. The role of influenza and parainfluenza infections in nasopharyngeal pneumococcal acquisition among young children. *Clin Infect Dis* **2014**; 58(10): 1369-76.
3. Karppinen S, Terasjarvi J, Auranen K, et al. Acquisition and Transmission of *Streptococcus pneumoniae* Are Facilitated during Rhinovirus Infection in Families with Children. *Am J Respir Crit Care Med* **2017**; 196(9): 1172-80.
4. DeMuri GP, Gern JE, Eickhoff JC, Lynch SV, Wald ER. Dynamics of Bacterial Colonization With *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection. *Clin Infect Dis* **2018**; 66(7): 1045-53.
5. Thors V, Christensen H, Morales-Aza B, et al. High-density Bacterial Nasal Carriage in Children Is Transient and Associated With Respiratory Viral Infections-Implications for Transmission Dynamics. *Pediatr Infect Dis J* **2019**; 38(5): 533-8.
6. Miellet WR, van Veldhuizen J, Nicolaie MA, et al. Influenza-like Illness Exacerbates Pneumococcal Carriage in Older Adults. *Clin Infect Dis* **2020**.
7. Ramos-Sevillano E, Wade WG, Mann A, et al. The Effect of Influenza Virus on the Human Oropharyngeal Microbiome. *Clin Infect Dis* **2019**; 68(12): 1993-2002.
8. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathog* **2013**; 9(1): e1003057.
9. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. *Nat Rev Microbiol* **2014**; 12(4): 252-62.
10. Vissers M, Ahout IM, van den Kieboom CH, et al. High pneumococcal density correlates with more mucosal inflammation and reduced respiratory syncytial virus disease severity in infants. *BMC Infect Dis* **2016**; 16: 129.
11. Howard LM, Zhu Y, Griffin MR, et al. Nasopharyngeal Pneumococcal Density during Asymptomatic Respiratory Virus Infection and Risk for Subsequent Acute Respiratory Illness. *Emerg Infect Dis* **2019**; 25(11): 2040-7.
12. Jochems SP, Marcon F, Carniel BF, et al. Inflammation induced by influenza virus impairs human innate immune control of pneumococcus. *Nat Immunol* **2018**; 19(12): 1299-308.
13. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health* **2021**; 3(6): e360-e70.
14. Amin-Chowdhury Z, Aiano F, Mensah A, et al. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England. *Clin Infect Dis* **2021**; 72(5): e65-e75.
15. Danino D, Ben-Shimol S, van der Beek BA, et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. *Clin Infect Dis* **2022**; 75(1): e1154-e64.
16. Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. *Lancet Microbe* **2021**; 2(8): e354-e65.
17. Lewnard JA, Bruxvoort KJ, Fischer H, et al. Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between *Streptococcus pneumoniae* and SARS-CoV-2 in the respiratory tract. *J Infect Dis* **2021**.
18. Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. *Clin Microbiol Infect* **2021**; 27(1): 61-6.
19. Cucchiari D, Pericas JM, Riera J, et al. Pneumococcal superinfection in COVID-19 patients: A series of 5 cases. *Med Clin (Engl Ed)* **2020**; 155(11): 502-5.
20. Willen L, Ekinci E, Cuyppers L, Theeten H, Desmet S. Infant Pneumococcal Carriage in Belgium Not Affected by COVID-19 Containment Measures. *Front Cell Infect Microbiol* **2021**; 11: 825427.

- 365 21. Kolodziej LM, van Lelyveld SF, Haverkort ME, et al. High SARS-CoV-2 Household Transmission Rates Detected  
366 by Dense Saliva Sampling.
- 367 22. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.  
368 Euro Surveill **2020**; 25(3).
- 369 23. Trzcinski K, Bogaert D, Wyllie A, et al. Superiority of trans-oral over trans-nasal sampling in detecting  
370 Streptococcus pneumoniae colonization in adults. PLoS One **2013**; 8(3): e60520.
- 371 24. Carvalho Mda G, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR assays  
372 targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. J Clin Microbiol **2007**; 45(8): 2460-6.
- 373 25. Miellet WR, van Veldhuizen J, Litt D, et al. It Takes Two to Tango: Combining Conventional Culture With  
374 Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal  
375 Serogroup/Serotype Determination in Carriage. Front Microbiol **2022**; 13: 859736.
- 376 26. Miellet WR, van Veldhuizen J, Litt D, et al. A Spitting Image: Molecular Diagnostics Applied to Saliva Enhance  
377 Detection of Streptococcus pneumoniae and Pneumococcal Serotype Carriage. **Unpublished results**.
- 378 27. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability  
379 Research. J Chiropr Med **2016**; 15(2): 155-63.
- 380 28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical  
381 measurement. Lancet **1986**; 1(8476): 307-10.
- 382 29. Hothorn T, Hornik K, van de Wiel MA, Zeileis A. Implementing a Class of Permutation Tests: The coin Package  
383 Journal of Statistical Software **2008**; 28(8).
- 384 30. Li Y, Peterson ME, Campbell H, Nair H. Association of seasonal viral acute respiratory infection with  
385 pneumococcal disease: a systematic review of population-based studies. BMJ Open **2018**; 8(4): e019743.
- 386 31. Han AX, Kozanli E, Koopsen J, et al. Regional importation and asymmetric within-country spread of SARS-  
387 CoV-2 variants of concern in the Netherlands. Elife **2022**; 11.
- 388 32. Reukers D, van Asten L, Brandsema P, et al. Annual report Surveillance of COVID-19, influenza and other  
389 respiratory infections in the Netherlands: winter 2020/2021. Surveillance van COVID-19, griep en andere  
390 luchtweginfecties: winter 2020/2021: Rijksinstituut voor Volksgezondheid en Milieu RIVM, **2021**.
- 391 33. Aykac K, Ozsurekci Y, Cura Yayla BC, et al. Pneumococcal carriage in children with COVID-19. Hum Vaccin  
392 Immunother **2021**; 17(6): 1628-34.
- 393 34. Parker AM, Jackson N, Awasthi S, et al. Association of upper respiratory Streptococcus pneumoniae  
394 colonization with SARS-CoV-2 infection among adults. Clin Infect Dis **2022**.
- 395 35. Mitsi E, Reine J, Urban BC, et al. Streptococcus pneumoniae colonization associates with impaired adaptive  
396 immune responses against SARS-CoV-2. J Clin Invest **2022**.
- 397 36. Walsh KA, Spillane S, Comber L, et al. The duration of infectiousness of individuals infected with SARS-CoV-2.  
398 J Infect **2020**; 81(6): 847-56.
- 399 37. de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, et al. Dysbiosis of upper respiratory tract microbiota in  
400 elderly pneumonia patients. ISME J **2016**; 10(1): 97-108.
- 401 38. Merenstein C, Liang G, Whiteside SA, et al. Signatures of COVID-19 Severity and Immune Response in the  
402 Respiratory Tract Microbiome. mBio **2021**; 12(4): e0177721.
- 403 39. Miellet WR, van Veldhuizen J, Litt D, et al. It Takes Two to Tango: Combining Conventional Culture with  
404 Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal  
405 Serogroup/Serotype determination in Carriage. medRxiv **2021**.

**Table 1 : Study participant characteristics**

Group	Overall (n=274)	SARS-CoV-2 infected (n=177)	SARS-CoV-2 uninfected (n=97)	<i>S. pneumoniae</i> carriers (n=160)	<i>S. pneumoniae</i> noncarriers (n=114)	Co-infected (n=106)
median age, years (range)	32 (0-64)	32 (0-63)	30 (1-64)	17 (1-63)	42 (0-64)	22 (1-63)
age group, n (%)						
< 12	51 (18.6)	29 (16.4)	22 (22.7)	45 (28.4)	6 (5.3)	25 (23.6)
12-17	47 (17.2)	31 (17.5)	16 (16.5)	36 (22.5)	11 (9.6)	25 (23.6)
18-39	65 (23.7)	49 (27.7)	16 (16.5)	31 (19.4)	34 (29.8)	25 (23.6)
40-49	74 (27.0)	44 (24.9)	30 (30.9)	35 (21.9)	39 (34.2)	21 (19.8)
50-65	37 (13.5)	24 (13.6)	13 (13.4)	13 (8.1)	24 (21.1)	10 (9.4)
sex, n (%)						
male	135 (49.3)	87 (49.2)	48 (49.5)	85 (53.1)	50 (43.9)	56 (52.8)
female	139 (50.7)	90 (50.8)	49 (50.5)	75 (46.9)	64 (56.1)	50 (47.2)
comorbidities, n (%)						
symptomatic, n (%)	30 (10.9)	14 (7.9)	16 (16.5)	14 (8.8)	16 (14.0)	7 (6.6)
median household size, n (range)	4 (3-6)	4 (3-6)	4 (3-6)	4 (3-6)	4 (3-6)	4 (3-6)
presence of a child aged <5 years in a household, n (%)	54 (19.7)	37 (20.9)	17 (17.5)	48 (30.0)	6 (5.3)	31 (29.2)



409

**Table S1: Rates across study observation period**

Group	T=1	T=3	T=5	T=7	T=10	T=14	T=21	T=28	T=35	T=42
SARS-CoV-2 infection, n (%)	153 (55.8)	159 (58.0)	151 (55.1)	150 (54.7)	138 (50.4)	115 (42.0)	77 (28.1)	56 (20.4)	22 (8.0)	17 (6.2)
pneumococcal carriage, n (%)	92 (33.6)	107 (39.1)	114 (41.6)	115 (42.0)	117 (42.7)	114 (41.6)	106 (38.7)	118 (43.1)	120 (43.8)	104 (38.0)

410

411

Observed SARS-CoV-2 infection and *S. pneumoniae* carriage rates across the six week study period among 274 individuals, including 98 children and 176 non-elderly adults.

412 **Table S2 : SARS-CoV-2 infection acquisition model selection**

Model	Coefficient (95% CI)	P-value	AIC
Model I:			188.13
log-transformed <i>piaB</i> abundance	1.14 (0.99 – 1.31)	0.065	
Model II:			191.10
log-transformed 16S abundance	0.87 (0.59 – 1.29)	0.487	
Model III:			189.55
log-transformed <i>piaB</i> abundance	1.14 (0.99 – 1.31)	0.096	
log-transformed 16S abundance	0.86 (0.57 – 1.27)	0.686	
Model IV:			189.55
log-transformed <i>piaB</i> abundance	1.14 (1.01 – 1.29)	0.038	
log-transformed 16S abundance	0.86 (0.58 – 1.27)	0.673	

413 AIC: Akaike information criterion, Number of included events were n=24.

414

415

**Table S3 : SARS-CoV-2 infection clearance model selection**

Model	Coefficient (95% CI)	P-value	AIC
Model I:			1343.01
log-transformed <i>piaB</i> abundance	0.90 (0.85 – 0.96)	0.002	
Model II:			1331.37
log-transformed 16S abundance	0.71 (0.62 – 0.82)	<0.0001	
Model III:			1328.12
log-transformed <i>piaB</i> abundance	0.92 (0.86 – 0.98)	<0.001	
log-transformed 16S abundance	0.73 (0.64 – 0.86)	<0.001	
Model IV*:			1326.15
log-transformed <i>piaB</i> abundance for T<21	0.90 (0.82 – 0.99)	0.025	
log-transformed <i>piaB</i> abundance for T≥21	0.93 (0.85 – 1.02)	0.149	
log-transformed 16S abundance for T<21	0.65 (0.55 – 0.78)	<0.0001	
log-transformed 16S abundance for T≥21	0.89 (0.70 – 1.13)	0.343	

416


AIC: Akaike information criterion. Number of included events were n=192. T: sampling event wherein T<21 indicates the 0-21 subinterval and T≥21 indicates the 21-42 interval.

417

\*: Based on exploratory analysis, we allowed some flexibility in the modeling by estimating time-varying effects of covariates. We divided the follow-up interval in two subintervals [0-21) and [21-42] and estimated piece-wise constant regression coefficients


418

419




420  
421  
422  
423  
424  
425  
426  
427  
428

**Figure 1: (A) Scatter plot displaying  $C_q$  *piaB* and *lytA* quantification for all individuals (n=274) and all samples (n=2740). (B) Bland-Altman plot displaying the extent of agreement in quantitative  $C_q$  measurements for *piaB* and *lytA* among positive samples.** Samples were classified as positive when measurements for *piaB* and *lytA* were both <40  $C_q$  (indicated by dashed lines). Red and blue dots represent samples positive and negative for *S. pneumoniae*, respectively. Numbers coloured red indicate the number of samples classified as positive for pneumococcus and black. ICC: intraclass correlation coefficient - a single score intraclass correlation coefficient with two-way model (consistency) was used for reliability analysis. The Bland-Altman plot illustrates the degree of agreement between *piaB* and *lytA*  $C_q$  measurements among positive samples. The mean difference in measurements is indicated by a dashed grey line and the standard deviations of the mean, upper limit of agreement (ULoA), and lower limit of agreement (LLoA) are also shown. In this Bland-Altman plot differences above the line of equality, indicated by a solid line, are for samples of which *lytA*  $C_q$ s were lower than *piaB*  $C_q$ s. ICC values <0.50, 0.50-0.75, 0.75-0.90 and >0.90 are indicative of poor, moderate, good, and excellent reliability, respectively.




**Figure 2: Alluvial diagram displaying longitudinal changes across the study period in participant status for SARS-CoV-2 infection and pneumococcal carriage among n=274 participants.** Infected noncarriers, infected carriers, uninfected carriers, uninfected noncarriers are colored in blue, red, yellow and green, respectively. Percentages of groups are shown in bars. The right y-axis indicates the number of individuals.




**Figure 3: Boxplots of SARS-CoV-2 viral loads from individuals positive for SARS-CoV-2 since study onset (t=1) and stratified by pneumococcal carriage status (A) and overall bacterial abundance (B).** Viral loads were compared blocked by age group (< 18 years old or  $\geq$  18 years old) with a permutation test equivalent of Mann-Whitney U test. Pneumococcal carriers display significantly increased viral loads at day 3, 5, 10 and 28 of study period when compared with noncarriers. Individuals with increased bacterial abundance display significantly increased viral loads at day 1, 5, 7, 10 and 21 of study period when compared with individuals with reduced bacterial abundance. Medians are indicated by a solid line in a boxplot.







**Figure S1: Scatter plot displaying C<sub>q</sub> measurements for *piaB* and *lytA* targets for all individuals at individual sampling events.** Red and blue dots represent samples positive and negative for *S. pneumoniae*, respectively. Samples were considered to be positive for *S. pneumoniae* when C<sub>q</sub> for both *piaB* and *lytA* were below 40 C<sub>q</sub>, the C<sub>q</sub> threshold is indicated by dashed lines. Numbers coloured red indicate the number of samples classified as positive for pneumococcus and black. ICC: intraclass correlation coefficient - a single score intraclass correlation coefficient with two-way model (consistency) was used for reliability analysis. ICC values <0.50, 0.50-0.75, 0.75-0.90 and >0.90 are indicative of poor, moderate, good, and excellent reliability, respectively.




**Figure S2:** (A) The survival probability of time to infection acquisition estimated by the non-parametric Kaplan-Meier estimator (in grey) and model-based (in black) and the respective 95% confidence intervals. While the two survival curves for children are virtually the same up to day 5, after day 5 the model-based curve slightly overestimates the non-parametric estimator. This difference is most likely due to the uncertainty of estimation caused by the reduced number of events after day 5 in our sample. (B) Predicted survival probabilities based on the Cox proportional hazards model (model IV of Table S2), stratified by age group, were compared for a participant with a relatively high pneumococcal abundance (high *piaB*) and average 16S abundance (overall bacterial abundance), represented by the dashed curves and a participant with relatively low pneumococcal abundance (low *piaB*) and average 16S abundance, represented by continuous curves. The continuous curves decrease at a lower rate than the dotted counterparts, illustrating the adverse effect of high *piaB* values on the rate of infection acquisition. Curves from children and adults are depicted in black and grey colours, respectively.




**Figure S3:** (A) The survival probability of time to infection acquisition estimated by the non-parametric Kaplan-Meier estimator (in grey) and model-based (in black) and the respective 95% confidence intervals. The two sets of curves are in agreement with each other, both for children and for adults. (B) Predicted survival probabilities based on the Cox proportional hazards model (model IV of Table S3), stratified by age group, were compared for a participant with a relatively high pneumococcal abundance (high *piaB*) and average 16S abundance (overall bacterial abundance), represented by the dashed curves and a participant with relatively low pneumococcal abundance (low *piaB*) and average 16S abundance, represented by continuous curves. The continuous curves decrease at a higher rate than the dotted counterparts, illustrating the impairing effect of high *piaB* values on SARS-CoV-2 infection clearance rates. Curves from children and adults are depicted with black and grey colours, respectively.



**Figure S4: (A) Pneumococcal abundances (*piaB*) of individuals that are identified as carrier for  $\geq 1$  sampling events, stratified by COVID-19 status. (B) Overall bacterial abundances from any individual irrespective of pneumococcal carriage status, stratified by COVID-19 status. The colour purple indicates positivity for SARS-CoV-2 infection. None of the sampling events display a significant difference in either pneumococcal abundances or overall bacterial abundance between individuals with or without a SARS-CoV-2 infection. A permutation test equivalent of the Mann-Whitney U test was used to compare abundances of SARS-CoV-2 infected and uninfected individuals while blocking by age groups ( $< 18$  years old or  $\geq 18$  years old).**



**Figure S5: Stacked bar diagrams of serotype sample composition per time point for (A) children and (B) adults. Analysis was limited to qPCR-targeted serotypes.** The percentage of serotypes or serogroups among pneumococcus positive samples are shown. Percentages are calculated per sampling event for children (<18 year olds) and adults ( $\geq 18$  year olds) separately. Results are limited to serotype-specific or serogroup-specific qPCR assays that produced at least one or more positive samples.



**Figure S6: Longitudinal SARS-CoV-2 viral load trajectories of pneumococcal carriers (A & B), and individuals with 16S abundance (C & D) were analyzed with linear mixed effects models.** Data from children (A & C) and adults (B & D) are modeled separately. Shaded areas indicate the 95% confidence interval of model estimates and the lines indicate the coefficients of model estimates. Censoring was applied to samples with a viral load of  $\geq 40$  Cq for the *Egene*. Pneumococcal carriers (A & B) are colored in red and noncarriers in blue. All individuals were positive for SARS-CoV-2 at T=1. Individuals with 16S abundances higher or equal to the median 16S abundance at T=1 are colored in green and individuals with 16S abundances below the median 16S abundance at T=1 are colored in yellow. None of the tested model exhibited significant differences in viral load trajectories for any of the analyzed groups.



## SUPPLEMENTAL TEXT

### Molecular Detection of Pneumococcal Serotypes

#### *qPCR-based Serotyping of Saliva Samples*

Per individual, DNA was extracted from pools of samples exclusively positive for *S. pneumoniae* and collected from a single person. For each individual, samples positive for *S. pneumoniae* were pooled in equal ratio and 200 µl of the pool (for individuals positive for *S. pneumoniae* only once, 200 µl of a single sample) was processed for nucleic acids extraction as described above. Serotype composition of pools was determined using a panel of primers and probes targeting serotypes 1, 3, 8, 14, 16F, 19A, 19F, 20, 21, 23A, 23B, 23F, 34 and 38, and serogroups 6A/B/C/D, 7A/F, 9A/L/N/V, 10A/B, 11A/D, 12A/B/C/F, 15A/B/C/F, 18A/B/C/F, 22A/F, 33A/F, 35B/C. When a pool of samples was positive for a serotype-specific or serogroup-specific qPCR assay all individual samples were also tested for that particular assay.

#### *Evaluation of Diagnostic Specificity of Serotype/Serogroup-specific qPCR Assays in Saliva*

Bland-Altman analysis was conducted to evaluate the specificity of serotype/serogroup-specific qPCR assays. Per sampling event, the upper limit of agreement between *piaB* and *lytA* was used as an a priori acceptable limit for agreement between serotype quantification and *piaB* or *lytA*. These limits ranged between 2.79 to 3.72 and were used to identify putative nonreliable results that exhibited strongly increased quantification of serotypes or serogroups when compared with quantification of *piaB* or *lytA*. In this analysis, serotypes 21 and 23A, and serogroups 9A/L/N/V, 12A/B/F, 33A/F and 35B/C were overrepresented and therefore all results from these assays were excluded from further analysis. Prior to exclusion of these qPCR assays, the mean ICC between dominantly ranked serotypes and *piaB* was 0.61, whereas after exclusion the mean ICC was 0.70.